drugset / Trial / NCT00542958
Study of NK012 in Patients With Refractory Solid Tumors
SequentialOpen-labelTreatment
Summary
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of refractory solid tumors
Timeline
- Start
- 2007-03
- Primary completion
- 2008-04
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 9 mg/m2 | Intravenous |
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 16 mg/m2 | Intravenous |
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 21 mg/m2 | Intravenous |
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 28 mg/m2 | Intravenous |